These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 15751738)

  • 1. Current approaches to developing a preventative HIV vaccine.
    Tonini T; Barnett S; Donnelly J; Rappuoli R
    Curr Opin Investig Drugs; 2005 Feb; 6(2):155-62. PubMed ID: 15751738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV/AIDS vaccines: 2007.
    Robinson HL
    Clin Pharmacol Ther; 2007 Dec; 82(6):686-93. PubMed ID: 17971817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [HIV/AIDS vaccines: heading for new vaccine approaches?].
    Girard MP
    Bull Soc Pathol Exot; 2008 Jun; 101(3):220-6. PubMed ID: 18681215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guérin: failures and challenges.
    Joseph J; Saubi N; Pezzat E; Gatell JM
    Expert Rev Vaccines; 2006 Dec; 5(6):827-38. PubMed ID: 17184220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrasting B cell- and T cell-based protective vaccines.
    Jansen VA; Altes HK; Funk GA; Wodarz D
    J Theor Biol; 2005 May; 234(1):39-48. PubMed ID: 15721034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in the development of an effective HIV vaccine: current approaches and future directions.
    Klein E; Ho RJ
    Clin Ther; 2000 Mar; 22(3):295-314; discussion 265. PubMed ID: 10963285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.
    Haynes BF; Montefiori DC
    Expert Rev Vaccines; 2006 Aug; 5(4):579-95. PubMed ID: 16989638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development.
    Betts MR; Gray CM; Cox JH; Ferrari G
    Expert Rev Vaccines; 2006 Aug; 5(4):505-16. PubMed ID: 16989631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes.
    Xu J; Ren L; Huang X; Qiu C; Liu Y; Liu Y; Shao Y
    AIDS; 2006 Nov; 20(18):2293-303. PubMed ID: 17117015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining DNA technologies and different modes of immunization for induction of humoral and cellular anti-HIV-1 immune responses.
    Bråve A; Hallengärd D; Malm M; Blazevic V; Rollman E; Stanescu I; Krohn K
    Vaccine; 2009 Jan; 27(2):184-6. PubMed ID: 18992294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a candidate DNA/MVA HIV-1 subtype C vaccine for India.
    Kumar S; Aggarwal P; Vajpayee M; Pandey RM; Seth P
    Vaccine; 2006 Mar; 24(14):2585-93. PubMed ID: 16480792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use.
    Thomson SA; Jaramillo AB; Shoobridge M; Dunstan KJ; Everett B; Ranasinghe C; Kent SJ; Gao K; Medveckzy J; Ffrench RA; Ramshaw IA
    Vaccine; 2005 Sep; 23(38):4647-57. PubMed ID: 15964105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress and obstacles in the development of an AIDS vaccine.
    Letvin NL
    Nat Rev Immunol; 2006 Dec; 6(12):930-9. PubMed ID: 17124514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV vaccine efficacy trials: towards the future of HIV prevention.
    Kim D; Elizaga M; Duerr A
    Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A safe, effective and affordable HIV vaccine--an urgent global need.
    Joseph J; Etcheverry F; Alcami J; María GJ
    AIDS Rev; 2005; 7(3):131-8. PubMed ID: 16302460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses.
    Bråve A; Hallengärd D; Schröder U; Blomberg P; Wahren B; Hinkula J
    Vaccine; 2008 Sep; 26(40):5075-8. PubMed ID: 18450334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional CD8+ CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine.
    Belyakov IM; Ahlers JD
    Trends Immunol; 2008 Nov; 29(11):574-85. PubMed ID: 18838298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 vaccine clinical trials: the Brazilian experience.
    Ersching J; Pinto AR
    Rev Med Virol; 2009 Sep; 19(5):301-11. PubMed ID: 19650156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design.
    Cagigi A; Nilsson A; De Milito A; Chiodi F
    Vaccine; 2008 Jun; 26(24):3016-25. PubMed ID: 18164520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Building on the past to define an efficient path to an HIV vaccine.
    Korber B
    Expert Rev Vaccines; 2011 Jul; 10(7):929-31. PubMed ID: 21806390
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.